Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial

By afschroeder • August 14, 2025

Turner NA, Hamasaki T, Doernberg SB, Lodise TP, King HA, Ghazaryan V, Cosgrove SE, Jenkins TC, Liu C, Sharma S, Zaharoff S, Wahid L, Renard VJ, Cook P, Raad I, Hachem R, Chaftari AM, Sims M, DeMarco C, Miller LG, McCarthy MW, Morse CG, Lucasti C, Forrest GN, Cherabuddi K, Polk C, Fazili T, Rupp ME, Thompson GR 3rd, Kim K, Strnad L, Schnee AE, McKinnell JA, Ramesh M, Silveira FP, McCarty TP, Lee TC, McDonald EG, Paolino K, Wiegand K, Wall A, Riccobene T, Patel R, Rappo U, Evans S, Chambers HF, Fowler VG Jr, Holland TL; Antibacterial Resistance Leadership Group. Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial. JAMA. 2025 Aug 13. doi: 10.1001/jama.2025.12543. Epub ahead of print. PMID: 40802264.

Tags: Harbor UCLA, Infectious Diseases, Publications

Evaluating Asparaginase Toxicity in Hispanic Patients With Acute Lymphoblastic Leukemia in a Large Safety-Net Hospital

Zheng D, Dragan M, Jang J, Tomassetti S. Evaluating Asparaginase Toxicity in Hispanic Patients With Acute Lymphoblastic Leukemia in a Large Safety-Net Hospital. World J[...]

Effects of purified eicosapentaenoic acid versus mixed eicosapentaenoic/docosahexaenoic acid pharmacotherapies on coronary plaque volume: network meta-analysis of prospective coronary imaging trials

Sheppard JP, Lakshmanan S, Palatnic L, Dahal S, Roy SK, Bhatt DL, Budoff MJ, Nelson JR. Effects of purified eicosapentaenoic acid versus mixed eicosapentaenoic/docosahexaenoic acid[...]

Use of CT-derived non-cardiovascular calcification marker for predicting cardiovascular events among diabetic older adults: the multi-ethnic study of atherosclerosis

Ghotbi E, Bluemke DA, Hathaway QA, Klein JG, Shabani M, Akhtarkhavari S, Barr RG, Bancks MP, Post WS, Budoff M, Lima JAC, Demehri S. Use[...]